Literature DB >> 18549459

Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients.

F L Lanza1, U K Marathi, B S Anand, L M Lichtenberger.   

Abstract

BACKGROUND: Chronic use of NSAIDs is associated with gastrointestinal (GI) toxicity that increases with age. AIM: To evaluate the GI safety and therapeutic efficacy of ibuprofen chemically associated with phosphatidylcholine (PC) in osteoarthritic (OA) patients.
METHODS: A randomized, double-blind trial of 125 patients was performed. A dose of 2400 mg/day of ibuprofen or an equivalent dose of ibuprofen-PC was administered for 6 weeks. GI safety was assessed by endoscopy. Efficacy was assessed by scores of analgesia and anti-inflammatory activity. Bioavailability of ibuprofen was pharmacokinetically assessed.
RESULTS: Ibuprofen-PC and ibuprofen provided similar bioavailability/therapeutic efficacy. In the evaluable subjects, a trend for improved GI safety in the ibuprofen-PC group compared with ibuprofen that did not reach statistical significance was observed. However, in patients aged >55 years, a statistically significant advantage for ibuprofen-PC treatment vs. ibuprofen in the prevention of NSAID-induced gut injury was observed with increases in both mean Lanza scores and the risk of developing >2 erosions or an ulcer. Ibuprofen-PC was well tolerated with no major adverse events observed.
CONCLUSION: Ibuprofen-PC is an effective osteoarthritic agent with an improved GI safety profile compared with ibuprofen in older OA patients, who are most susceptible to NSAID-induced gastroduodenal injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549459      PMCID: PMC3353548          DOI: 10.1111/j.1365-2036.2008.03765.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

1.  Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.

Authors:  F K Chan; S C Chung; B Y Suen; Y T Lee; W K Leung; V K Leung; J C Wu; J Y Lau; Y Hui; M S Lai; H L Chan; J J Sung
Journal:  N Engl J Med       Date:  2001-03-29       Impact factor: 91.245

2.  Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

Authors:  Julia Hippisley-Cox; Carol Coupland; Richard Logan
Journal:  BMJ       Date:  2005-12-03

3.  A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology.

Authors:  F L Lanza
Journal:  Am J Gastroenterol       Date:  1998-11       Impact factor: 10.864

4.  Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.

Authors:  F L Lanza; M F Rack; T J Simon; H Quan; J A Bolognese; M E Hoover; F R Wilson; S E Harper
Journal:  Aliment Pharmacol Ther       Date:  1999-06       Impact factor: 8.171

5.  NSAID ulcers: prevalence and prevention.

Authors:  D Y Graham
Journal:  Mod Rheumatol       Date:  2000-03       Impact factor: 3.023

6.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

7.  Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects.

Authors:  B S Anand; J J Romero; S K Sanduja; L M Lichtenberger
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

8.  Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis.

Authors:  D M Chang; T H Young; C T Hsu; S Y Kuo; T C Hsieh
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

9.  Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently.

Authors:  A Hackelsberger; U Platzer; M Nilius; V Schultze; T Günther; J E Dominguez-Muñoz; P Malfertheiner
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 10.  Aging, the gastrointestinal tract, and risk of acid-related disease.

Authors:  David A Greenwald
Journal:  Am J Med       Date:  2004-09-06       Impact factor: 4.965

View more
  22 in total

Review 1.  Role of dietary phospholipids and phytosterols in protection against peptic ulceration as shown by experiments on rats.

Authors:  Frank I Tovey
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.

Authors:  Yan Huang; Lenard M Lichtenberger; Morgan Taylor; Justin N Bottsford-Miller; Monika Haemmerle; Michael J Wagner; Yasmin Lyons; Sunila Pradeep; Wei Hu; Rebecca A Previs; Jean M Hansen; Dexing Fang; Piotr L Dorniak; Justyna Filant; Elizabeth J Dial; Fangrong Shen; Hiroto Hatakeyama; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2016-09-16       Impact factor: 6.261

3.  Role of phospholipids in protection of the GI mucosa.

Authors:  Lenard M Lichtenberger
Journal:  Dig Dis Sci       Date:  2013-04       Impact factor: 3.199

Review 4.  Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.

Authors:  John L Wallace
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

Review 5.  Convergence of nanotechnology and cancer prevention: are we there yet?

Authors:  David G Menter; Sherri L Patterson; Craig D Logsdon; Scott Kopetz; Anil K Sood; Ernest T Hawk
Journal:  Cancer Prev Res (Phila)       Date:  2014-07-24

Review 6.  NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies.

Authors:  John L Wallace
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

7.  Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine.

Authors:  Lenard M Lichtenberger; Yong Zhou; Vasanthi Jayaraman; Janice R Doyen; Roger G O'Neil; Elizabeth J Dial; David E Volk; David G Gorenstein; Mohan Babu Boggara; Ramanan Krishnamoorti
Journal:  Biochim Biophys Acta       Date:  2012-04-14

8.  Aggregation behavior of ibuprofen, cholic acid and dodecylphosphocholine micelles.

Authors:  Priyanka Prakash; Abdallah Sayyed-Ahmad; Yong Zhou; David E Volk; David G Gorenstein; Elizabeth Dial; Lenard M Lichtenberger; Alemayehu A Gorfe
Journal:  Biochim Biophys Acta       Date:  2012-08-04

9.  Design and evaluation of a novel nanodrug delivery system for reducing the side effects of clomiphene citrate on endometrium.

Authors:  Marziyeh Ajdary; Fariborz Keyhanfar; Reza Aflatoonian; Amir Amani; FatemehSadat Amjadi; Zahra Zandieh; Mehdi Mehdizadeh
Journal:  Daru       Date:  2020-06-02       Impact factor: 3.117

10.  Growth inhibitory effects of PC-NSAIDs on human breast cancer subtypes in cell culture.

Authors:  Shelley Burge; Lenard M Lichtenberger
Journal:  Oncol Lett       Date:  2019-10-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.